Abstract: Coated activated charcoal haemoperfusion (CAC-HP) is a well-known treatment modality. Case reports have revealed conflicting results about the efficacy of CAC-HP in the treatment of amitriptyline (AT) poisoning, and no randomized clinical trials have been identified in the literature. This study aimed at quantifying the efficacy of modern CAC-HP as an adjunctive treatment of AT intoxication compared with standard care alone. Fourteen female Danish landrace pigs were randomized to either standard care or standard care plus 4 hr of CAC-HP. The pigs were anaesthetized, and vital parameters were continuously recorded. Amitriptyline infusion (7.5 mg/kg) was completed in 20 min. Thirty minutes after AT infusion, activated charcoal was instilled orally in both groups. In the intervention group, CAC-HP was initiated 60 min. after AT infusion. Blood and urine samples were collected as were vital parameters at specific time intervals. The protocol was approved by the Danish Experimental Animal Expectorate and complied with the NIH guide for care and use of laboratory animals. Data were managed according to the ARRIVE guidelines. No statistical significant differences between intervention and control groups were found when analysing for differences in AT levels in plasma at any time-point. Furthermore, significant differences between the control and intervention groups in regard to vital parameters could not be found either. In our animal model, the addition of CAC-HP did not improve the clearance of AT compared with standard treatment alone. We suggest that the effect of modern CAC-HP as a treatment modality in AT-poisoned human patients may be inadequate.
Most medicines used today possess intrinsic toxicity, which may be identified as adverse events when taken as prescribed or as potentially life-threatening poisoning when ingested in overdoses.
Data regarding the pattern of poisonings are provided by the National Poisons Control Centres around the world -data which reveal an increase in the number of clinically relevant human intoxications with both prescription and non-prescription drugs, drugs-of-abuse and chemical compounds [1, 2] . Data from the Danish Poisons Information Center support this picture and reveal that the number of enquiries from healthcare professionals and the public in general regarding poisonings with medicines is increasing [3] . The psychoactive drugs are of particular importance due to the known cardio toxic effects [4] .
An example is the tricyclic antidepressant drug amitriptyline (AT), used in the treatment of depression (acute and atypical depression). Amitriptyline is moreover used as an analgesic for neuropathic pain condition and fibromyalgia [5] [6] [7] . Side effects are dominated by severe disturbance in heart rhythm, anticholinergic effects, peripheral nervous symptoms and CNS depression and hypotension [4, [8] [9] [10] [11] [12] [13] [14] .
The use of activated charcoal filters (coated and non-coated) as an adjunct to the extracorporeal treatment (ECT) of AT intoxications is not widely applied, and only few cases are reported with varying degree of effect [9, 15, 16] . Likewise, we find the indication for initiating treatment involving ECT including coated activated charcoal filters (CAC-HP) vague and the evidence low [17] . Accordingly, a literature search in PubMed and EMBASE has not been able to identify any controlled clinical toxicological studies concerning CAC-HP. However, a few reviews, some case reports and case series regarding the use of CAC-HP were identified -and all of them support the demand for controlled trials [18] . Clinical trials involving human low-level intoxications are very difficult to perform, and a randomized human trial is ethically prohibitive and will never be able to reveal in a controlled manner what happens in the severely poisoned patient. In the absence of such human studies, there is a profound need for technically and phenotypically well-characterized large animal in vivo models allowing the study of severe and potentially life-threatening medical poisonings.
The current study was a randomized, controlled trial seeking to quantify the efficacy of modern CAC-HP in the severely AT-poisoned pig.
Material and Methods
The hypothesis to be tested in this study was that CAC-HP lowers the plasma level of AT in the AT-poisoned pig. The rationale for this hypothesis is that CAC adsorbs AT and thereby eliminates AT from plasma resulting in a lower plasma concentration and lower risk of development of a clinically severe poisoning. The study protocol was approved by the Danish Experimental Animal Expectorate (2014-15-0201-00190) and complies with the NIH guide for care and use of laboratory animals, eighth edition.
The study was conducted in the animal research laboratory at the Department of Veterinary Clinic and Animal Science, University Hospital for Companion Animals and the Department of Experimental Medicine, Faculty of Health, University of Copenhagen, Denmark.
The study methodology complies with the concept of the 3Rs [19, 20] . Fourteen female Danish landrace pigs were included.
Experimental. All animals were kept in uniform conditions prior to enrolment in the trial. Water was available at all times. The animal caretakers administered the food in accordance with the animal's needs. The animals were housed for a minimum of 1 week prior to enrolment in the study. The day before the trail day, the animals were sedated with 10 mg/kg of ketamine, 40 lg/kg of dexmedetomidine and 0.2 mg/kg of butorphanol and intramuscular (IM) and intravenous (IV) access was secured in both ears.
At the trail day and before anaesthesia, the animals were randomized by random numbers in a sealed envelope to either intervention (CAC-HP) or control group (CG) [21, 22] and then anaesthetized in their pens by intravenous induction with propofol (B.Braun, Copenhagen, Denmark) 4-6 mg/kg IV and titrated until effect.
While on spontaneous respiration, the pigs were transported to the laboratory facility.
The animals were continuously monitored during the experiment using three-lead ECG and pulse oximetry probe (Datex-Ohmeda AS/3 Division Instruments Corp., Helsinki, Finland). Intubation was commenced and mechanically ventilation initiated. Anaesthesia was maintained by inhalation of sevoflurane 2-2.5%. Respiratory setting was targeted at normoventilation (GE Datex-Ohmeda Avance S5, Brøndby, Denmark). Inspiratory oxygen fraction (FiO 2 ) was set at 60%. Analgesia was maintained by bolus of fentanyl 500 lg followed by controlled infusion of 100-150 lg/kg/hr.
Bladder catheter (6-8 F Mila Corporation) was inserted and location of the tip assured by clear urine. A rectal temperature probe (Datex--Ohmeda AS/3 Division Instruments Corp) was installed. Using aseptic technique, a venous cut-down was performed after analgesia with 8 ml of lidocaine 2%. The femoral vein and artery were located and cannulated. In the control group, an arterial line (AL) and bilumen central venous catheter was inserted.
In the CAC-HP-group, the same procedure was performed, but a 15-cm bilumen haemodialysis catheter (Dolphin, Baxter-Gambro, Albertslund, Denmark) was inserted instead of the central venous catheter.
After installation of the catheters, all lines were filled with heparin 500 IU/ml to prevent occlusion.
A patient monitor (Datex-Ohmeda AS/3 Division Instruments Corp) was connected to obtain vital parameters. Invasive blood pressure was obtained via the AL in the femoral artery. The same AL was used for arterial blood gases. Data were recorded in real time using proprietary software (VitalSignsCapture, https://sourceforge.net/projects/vscapture/ August2016) with sampling frequency every 1 min.
The peripheral vein catheters placed in the ears were used for fluid maintenance and AT loading. Ringers solution (Fresenius Kabi, Copenhagen, Denmark) was infused by volume-controlled pump (Heska Vet/IV 2.2; Loveland, CO, USA). Fluid infusion was stopped during AT infusion. After the preparation, the animals were not manipulated for a period of at least 30 min. to stabilize before baseline data were recorded. Baseline data (haemodynamic and respiratory parameters) were then recorded for a minimum of 15 min. before a baseline 12-lead ECG was obtained. Amitriptyline (Amitriptyline 10 mg/ml, Pharmacy of Bispebjerg University Hospital, 2400 Copenhagen, Denmark) loading was initiated with 7.5 mg/ kg for 20 min. (TERUFUSION Syringe Pump TE-331; Terumo, Leuven, Belgium). When AT loading was completed, a time-0 sample and 12-lead ECG was carried out followed by 30 min. of AT distribution ( fig. 1) .
A soft rubber gastric tube was inserted and oral activated charcoal (1 g/kg) (Norit Carbomix; Aage Christensen A/S, Valby, Denmark) was instilled 30 min. after completion of AT infusion. Haemoperfusion was initiated in the CAC-HP group 30 min. after activated charcoal dosing. The pigs in the CAC-HP group were anticoagulated with heparin to an activated clotting time above 400 sec. The CAC-HP blood flow was set at 50 ml/min. equalling 3000 ml/h for the entire duration of the CAC-HP period. The CAC filter contained 150 g activated charcoal with a surface area of 1000 m 2 /g.
Measurements.
Data measurements including EGG, heart rate, blood pressure, temperature, respiratory rate and end-tidal CO 2 (ETCO 2 ) were recorded for 15 min. after 30 min. of stabile anaesthesia and served as baseline values. Vital parameters were obtained every 1 min. and continued throughout the remaining study day. To compare acid-base balance between the groups, arterial gases were carried out regularly in both the CAC-HP and the CG groups. Blood and urine samples were collected throughout the study day to obtain an AT time-concentration profile. For the determination of AT concentration in serum, venous blood samples were drawn from the CVC by dry tube vacutainers (BD, NJ, USA). A total of 13 samples from each pig were collected at baseline before AT infusion, at the termination of AT infusion T0, and at 15, 30, 45, 60, 75, 90, 120, 180, 240, 320 and 380 min. after AT infusion. In the CAC-HP group, samples were drawn before and after filter during the CAC-HP procedure. After extraction, the samples were allowed to coagulate for a maximum of 30 min. before centrifugation and separation of serum. Two aliquots of 100 lL serum were extracted from each sample and stored at À20°C until analysis. Arterial gases from both groups were analysed to assure that potassium, sodium, blood glucose and gases were within normal ranges (GEMPremier 3000, Lexington, MA, USA). A schematic presentation of the execution of the trial is presented in fig 1. After final blood sampling and ECG recording, the animals were killed by intravenous bolus of pentobarbital 140 mg/kg (Euthasol Vet, Oudewater, The Netherlands). Within 10 min. after euthanasia, post-mortem section was performed and tissue samples were collected from septum and left ventricle of the heart, liver tissue, bile, fat tissue and muscle from the hind leg. A small craniotomy was performed, and cerebral fluid and cortex of the brain were collected. After thawing the serum samples, proteins were precipitated with acetonitrile containing internal standard nortriptyline D3 at a concentration of 1000 ng/ml at a ratio of 1:1. The samples were then vortexed for 30 sec. (Vortex Genie, Scientific Industries, New York, NY, USA) and centrifuged for 16 min. at 14,640 rpm equivalent to 20238 g (Centrifuge 5430; Eppendorf, New York, NY, USA). Sixty microL of the supernatant were then extracted and diluted with 60 lL Milli-Q water before analysis. Quantification of the AT concentration in plasma was carried out by high-performance liquid chromatography (Agilent 1100 Series, Agilent Technologies, Waldbronn, Germany) coupled to an ion trap mass spectrometer (Thermo Finnigan LCQ Deca XP plus; Thermo Scientific, Germany). The column was a Phenomenex Luna C18 [2] , 3 lm, 100 A. Analytes were eluted under isocratic conditions with a flow rate of 0.2 ml/min. Mobile phase composition is as follows: methanol /Milli-Q water (33:67) + 0.1% v/ v formic acid. The mass spectrometer was equipped with an electrospray ionization interface operated in the positive ionization mode. The following analytes were detected by single-ion monitoring: m/z 264 (AT) and m/z 267 (deuterated AT internal standard).
Quantification of urine-AT concentration. Urine was sampled at the same time-points as the venous blood samples, immediately frozen to À20°C and stored outside the trial facility at À80°C for later analysis.
Prior to analysis, the urine samples were subject to centrifugation followed by dilution with an appropriate amount of water. Urine samples containing haem were precipitated with an equal amount of acetonitrile followed by centrifugation. The supernatant was diluted with an appropriate amount of water prior to analysis.
Quantification of AT concentration in urine was carried out by high-performance liquid chromatography (Ultimate 3000; Thermo Scientific) coupled to triple quadrupole mass spectrometer (Finnigan TSQ Quantum Ultra; Thermo Scientific). The column was a Phenomenex Kinetex XB-C18 2.6 lm, 100 A, 100 9 2.1 mmID. The column was thermostated at 60°C. The mobile phases consisted of acetonitrile/ Milli-Q water (2:98) + 0.1% v/v formic acid (A) and acetonitrile/ Milli-Q water (95:5) + 0.1% v/v formic acid (B). AT was eluted under linear gradient conditions; 25-70% B over 3 min. followed by re-equilibration with 25% B. The flow rate was 0.5 ml/min. The mass spectrometer was equipped with an electrospray ionization interface operated in the positive ionization mode. AT was detected by single reaction monitoring: m/z 264 to m/z 233.
CAC adsorption capacity -in vitro set-up. To quantify the efficacy of the CAC, an in vitro model was constructed. The objective was to evaluate the possible adsorption reduction mediated by plasma as compared to non-plasma aqueous buffer, and to evaluate whether the coating per se had an impact on the adsorption capacity compared with non-coated AC (AC). Human plasma and aqueous buffer solution was spiked with AT at a concentration of 10,000 ng/ml AT hydrochloride salt. The adsorption of AT was tested against both charcoal formulas (CAC and AC).
Five millilitres of the spiked matrix was added to a plastic vial with a removable cap, and AC was added in quantities of 100, 200, 300, 400 and 500 mg. The vials were closed, carefully mixed and immediately placed in a water bath (37°C) for 3 hr with gentle shaking. To quantify the possible impact inflicted by plasma compounds on the adsorption capacity of AT to CAC, an adsorption experiment was carried out equal to the above mentioned, except the matrix varied in buffer:plasma ratio from 0:100 to 100:0. The pH was kept at 7.4 and the temperature stable to mimic physiological conditions. Statistical analysis. Mean values for each of the measurement parameters were calculated, and a baseline was set. Each of the following obtained measurements was compared to baseline, and a delta value for each sampling was calculated.
The means for every delta parameter was calculated likewise for the CAC-HP and the CG for every minute throughout the trial. The within-group standard deviation (S.D.) and the within-group standard error of the mean (S.E.M.) for every minute throughout the trial were calculated. Thereafter, the curve S.D. for the CAC-HP group and CG were calculated, thereby making it possible to graph the curves by sample means AE 2SD. Differences in AT concentration in plasma and urine were calculated by one-way ANOVA (IBM SPSS 24 statistics).
Results
A total of 14 pigs (mean weight 27.7 kg S.D. AE 5.3 kg (intervention group) and 24.4 kg AE 4.1 kg (control group)) were enrolled in the study, and 13 pigs completed the trial in accordance with the protocol and they were therefore included in the final analysis. One pig went into torsade de pointe dysrhythmia 22 min. after AT initiation and died. No significant differences in weight (p = 0.411), Ringer infusion dose (p = 0.467) and fentanyl dose (p = 0.064) between the two groups were found. The concentration of AT in serum was measured throughout the course of the trial as depicted in fig. 1 . No significant differences between the groups were observed at any time-point during the experiment (fig. 2) . The accumulated urine-AT concentration (ng/ml/kg) over time is shown in fig. 2B . Data were tested for equality of variances by Leven's test. Only at time-point 15 min. did we find a significant p-value (p = 0.02 and F = 13.875). At all other time-points, the p-values for Levene's test were from 0.052 to 0.833. We were interested in the between-group differences of accumulated AT in the urine over time and in total. The independent t-test revealed no significant differences between groups at any time-point (p > 0.124). In fig. 2B , it appears that the total excreted AT in urine is higher in the CAC-HP group compared with CG group, but this finding is not significant.
Haemodynamic parameters were split into mean arterial pressure (MAP), systolic pressure (SP) and diastolic pressure (DP). The measured respiratory parameter was ETCO 2 . MAP and ETCO 2 are shown in fig. 3 as mean AE 2SD. No significant differences were present as revealed also in the graphs where the confidence intervals (CI) intervals are overlapping. In the in vitro model, the fraction of AT adsorbed to CAC in aqueous and plasma solution was quantified ( fig. 4 and table 1 ).
Discussion
The primary aim of the current trial was to test whether CAC-HP could successfully be applied as an adjunctive treatment modality in severely AT-poisoned pigs and secondly to describe a model for studying CAC-HP in a large mammal model. One of the goals when doing animal research is to obtain data and knowledge that may be applied in the clinical work of physicians trying to treat poisoned patients. The dose of AT loading used in this trial was chosen to mimic the toxidrome of AT poisoning in human beings. Amitriptyline is considered potentially toxic to human beings in doses exceeding 2.5-5 mg/kg. Doses of 10-20 mg/kg are considered as an exposure associated with the risk of severe cardiovascular and neurological symptoms. However, the toxic dose varies and a specific lethal dose is not established. Children, in particular, are sensitive [23] .
Medical poisonings with psychotropic drugs are often critical and demanding. Due to the pharmacological complexity of the poisoning and severity of patient condition, hospitalization in intensive care unit setting for observation and intensive supportive care may be required. If a toxic substance is absorbable by AC, guidelines and advice from the Danish Poisons Information Centre include, for mildly to moderately poisoned patients, a recommendation of treatment with AC orally and monitoring of vital parameters [24, 25] . For tricyclic antidepressants, this includes continuous observation by telemetry, which is a pending and resource-consuming observational method, frequently exceeding 24 hr. A long observation period is stressful for the patient as well as the relatives and caregivers. In addition to poison-specific treatment, if possible, the standard treatment is directed at immediate basic and advanced life-sustaining procedures where interventions are triggered by complications inflicted by the toxin.
For several decades, ECT modalities have been used in various settings [17, 26] . The pioneer in the field of extracorporeal clearance was the US-born biochemist, John Jacob Abel, who in the seeking of a way to detoxify salicylate-poisoned patients made the first artificial kidney [27] . The CAC works by non-specific binding of substances by Van der Waals interactions and may therefore bind various substances which otherwise are not filtered or absorbed in the filters of standard high/low flux dialysis or continuous renal replacement therapy filters. Hence, substances or toxins with high volume of distribution (Vd) and low protein binding are often seen as the indication for applying the CAC-HP, although the efficacy is unknown.
Several case reports and case series regarding the use of CAC-HP involve the treatment of human intoxication with AT and other tricyclic antidepressants (TCA) [9, 15] . The authors sometimes state remarkable patient recovery in circulatory and cerebral performance and contribute this to the use of CAC-HP, although no serum AT samples were collected to quantify the effect of CAC-HP in these cases. It has been discussed whether CAC-HP should have a key role in the standard treatment protocol for the management of severe medical poisoning. Toxicokinetic parameters for high-dose intake of AT are not well established and theoretically the time to maximal serum concentration might be extended due to, for example, slower gastrointestinal absorption rate and transition from first-order kinetics into zero-order kinetics and a subsequent increase in serum concentration. Further, the elimination halflife might be prolonged if hepatic metabolism reaches saturation or if the liver function is otherwise compromised [28] .
Benefits from CAC-HP might theoretically be caused by a shift of the drug equilibrium from deeper compartments to the central compartment or a shift in the equilibrium between protein-bound and free drugs in the intravascular compartment. Advances in ECT, for example filters, dialysate, anticoagulation and catheters, may challenge existing data; thus, a toxin that was not considered dialysable 15 years ago may be dialysable or adsorbed today when applying modern techniques. An animal model for testing the efficacy of modern coated charcoal filters has not been described before. A pig model was chosen due to the size of the pig and its many similarities to human beings; especially, the tissue compartments are of importance when choosing the animal for the model. Other approaches to solve the issues regarding the use of laboratory animals were discussed in our group, but methods to replace the laboratory animal were not feasible if the research question had to be answered. The size was of importance in order to be able to translate HP flow rates to a human set-up. We applied flow rates in accordance with manufacture guidelines (BaxterGambro).
Most patients are poisoned with AT by large intake of tablets. We chose to AT-load the pigs intravenously in order to eliminate interindividual variations in AT absorption due to gastrointestinal factors [29] . Fig. 2 illustrates that the plasma concentration curve is identical for the two groups. It is interesting that the plasma concentration curves reveal a distribution of AT to the blood while the filter is active. Looking at the after-filter concentrations and the subsequent before-filter concentrations, the latter is higher than expected. This could be accounted for by redistribution via the enterohepatic pathway. The AT is secreted into the bile, released into the small intestine and then reabsorbed back into circulation. This pathway is described in earlier studies and reviews and is the reason why repeated orally given activated charcoal is recommended in AT poisonings [30] . In fig. 2 , it appears that the adsorption of AT is very limited and that the adsorption decreases and levels off by the end of therapy. To address this observation, an in vitro model was designed to assess the efficiency of AT adsorption by CAC. The CAC used in the in vitro model was isolated from the same CAC columns applied in the in vivo model. The objective was to evaluate the implication of endogenous plasma compounds on the filter efficacy. The experiment was designed to evaluate the saturation cut-off values for the CAC in plasma and aqueous buffer solutions at stable physiological temperatures and pH. We estimated that the circulating blood volume in the pigs was approximately 2600 ml. The filter applied contained 150 g charcoal with a surface area of 150,000 m 2 . The CAC available for the blood was approximately 60 mg/ml of blood. In the experiment, all samples had the same concentration of AT-HCL (10,000 ng/ml) and only the amount of AC added to the samples varied. Samples were tested at 100 mg, 200 mg, 400 mg and 500 mg of AC achieving a w/w ratio of AC/AT ranging from 2000:1 to 10,000:1. By comparison, the w/w ratio in the in vivo model was around 800:1 of CAC/AT. The levels of w/w were decided based on the paper by Heinonen et al. [31] who measured plasma AT levels around 10,000 ng/ml. The absence of spikes on the HPLC indicated that all AT was adsorbed. The in vitro data revealed a much larger adsorption in aqueous buffer solution than in plasma when comparing the amount of AC and CAC in a w/w relation 1:1. This indicates that a plethora of compounds in plasma in some way compromise the adsorption capacity of CAC. One reason may be that the CAC becomes saturated or clotted by plasma proteins, which compromises the adsorption capacity. Amitriptyline is excreted in the urine as unchanged AT and as the metabolite nortriptyline. In this trial, we measured only the AT alone in the urine. The volume of urine produced by the pigs was less than we expected, interindividual variation was high and no difference in volume between the two groups was found. Quantitative urine analysis for the metabolite nortriptyline should be included in further studies.
Conclusion
It was neither possible to extract AT from the blood stream nor to increase elimination of AT in AT-poisoned pigs by the use of CAC-HP. Furthermore, it was not possible to find any statistically significant differences in vital parameters between the intervention group receiving CAC-HP in addition to standard care and the control group (standard care alone). Although direct human extrapolation should be done with care, we conclude that the effect of modern CAC-HP as an adjunctive treatment modality in AT-poisoned human patients may be inadequate.
